Learn about Expert Review of Anticancer Therapy

Aims and scope

Expert Review of Anticancer Therapy [ISSN 1473-7140]; [e-ISSN 1744-8328] is a MEDLINE-indexed, international journal publishing comprehensive peer-reviewed content on the major issues in clinical oncology.

Coverage in the journal is focused on, but not limited to, the following key areas:

Anticancer agents
Novel therapies in development
Cancer management
Biomarkers
Diagnostics
Clinical trials
Treatment guidelines

The journal welcomes clinically focused original research, reviews, editorials and drug profile articles.

Please note that the journal does not accept case reports or case series and does not accept papers focused on pre-clinical work and/or animal studies.

Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.

Authors can choose to publish gold open access in this journal and may choose to publish using our Accelerated Publication services.

For any pre-submission enquiries, please contact the Commissioning Editor.

Journal metrics

Usage

236K annual downloads/views

Citation metrics

2.9 (2023) Impact Factor
Q2 Impact Factor Best Quartile
4.0 (2023) 5 year IF
5.1 (2023) CiteScore (Scopus)
Q2 CiteScore Best Quartile
0.688 (2023) SNIP
0.827 (2023) SJR

Speed/acceptance

2 days avg. from submission to first decision
73 days avg. from submission to first post-review decision
7 days avg. from acceptance to online publication
33% acceptance rate

Understanding and using journal metrics

Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.

We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.

For more details, please read the Author Services guide to understanding journal metrics.

Journal metrics in brief

Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).

Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.

Citation Metrics

Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.

Speed/acceptance

From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.

For more details on the data above, please read the Author Services guide to understanding journal metrics.

*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus

Editorial board

Editor-in-Chief: Gertjan JL Kaspers,

Amsterdam UMC, Emma Children’s Hospital and Vrije Universiteit Amsterdam;

Princess Máxima Center for pediatric oncology, Utrecht, The Netherlands

Richard J Ablin

, Arizona Cancer Center, USA

Jame Abraham

, Cleveland Clinic, USA

Michael B Atkins

, Beth Israel Deaconess Med. Center, USA

Jean-Yves Blay

, Leon Berard Center, Claude Bernard University, Lyon, France

Alba A. Brandes,

AUSL Bologna, Italy

Liang Cheng

, Indiana Uni. School of Medicine, USA

Angus G Dalgleish

, St George’s Hospital, UK

William S Dalton

, Lee Moffitt Cancer Ctr & Res. Inst., USA

Theo M. De Reijke,

Academic Medical Center, The Netherlands

Kapil Dhingra

, Hoffman-La Roche, USA

David S. Ettinger

, Johns Hopkins Oncology Center, USA

Alfio Ferlito

, University of Udine, Italy

Apar Kishor Ganti

, Nebraska Medical Center, USA

Antonio J Grillo-Lopez

, Clinical Research, USA

Peter J Hersey

, University of Newcastle, Australia

Eiso Hiyama

, Hiroshima University, Japan

Thomas E Hutson

, Baylor Sammons Cancer Center, TX, USA

David H Ilson

, Memorial Sloan Kettering Cancer Center, USA

Ashish M Kamat,

MD Anderson Cancer Center, USA

Fumitaka Koga

, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Simon S Lo

, Case Western Reserve University Comprehensive Cancer Center, USA

Hitendra HR Patel

, University College London, UK

Vipul R Patel

, The Ohio State University, OH, USA

Timothy M Pawlik

, The Ohio State University, Wexner Medical Center, Ohio, USA

Sara Pilotto,

University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy

Marshall R Posner

, Dana-Farber Cancer Institute, USA

Timothy Price

, The Queen Elizabeth Hospital, Australia

Edgardo Santos

, University of Miami Miller School of Medicine, USA

Dong Moon Shin

, Emory University School of Medicine, USA

Guru Sonpavde

, Dana-Farber Cancer Institute, Boston, USA

Elizabeth Smyth

, Cambridge University Hospitals NHS Foundation Trust, UK

Giuseppe Tonini

, University Campus Bio-Medico, Italy

Nico Van Zandwijk

, Sydney Medical School, Australia

Jan B Vermorken

, University Hospital, Belgium

Louis M Weiner

, Georgetown University Medical Center, USA

Sam M Wiseman

, Uni. British Columbia, Canada

Paul Workman

, Institute of Cancer Research, UK

Abstracting and indexing

Expert Review of Anticancer Therapy

is included in the following abstracting and indexing services:

Chemical Abstracts; CINAHL®Plus; Current Contents®/Clinical Medicine; EMBASE/Excerpta Medica; Index to Scientific Reviews®; Journal Citation Reports/Science Edition® ; MEDLINE/Index Medicus; Science Citation Index Expanded™ (SciSearch®); Scopus.

Open access

Expert Review of Anticancer Therapy is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.

Why choose open access?

Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article

Article Publishing Charges (APC)

If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.

Use our APC finder to calculate your article publishing charge

News, offers and calls for papers

News and offers

Discuss your submission with Commissioning Editor Rob McMinn

Advertising information

Would you like to advertise in Expert Review of Anticancer Therapy?

Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Expert Review of Anticancer Therapy.

Explore advertising solutions

Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .

Citation search

Jump to section

About this journal

Aims and scope

Journal metrics

Understanding and using journal metrics

Journal metrics in brief

Citation Metrics

Speed/acceptance

Editorial board

Abstracting and indexing

Open access

Why choose open access?

Article Publishing Charges (APC)

News, offers and calls for papers

News and offers

Calls for papers

Associated with:

Advertising information

Would you like to advertise in Expert Review of Anticancer Therapy?

Ready to submit?

Information for

Open access

Opportunities

Help and information

Citation search

Your download is now in progress and you may close this window

Login or register to access this feature

About this journal

Aims and scope

Journal metrics

Understanding and using journal metrics

Journal metrics in brief

Citation Metrics

Speed/acceptance

Editorial board

Abstracting and indexing

Open access

Why choose open access?

Article Publishing Charges (APC)

News, offers and calls for papers

News and offers

Calls for papers

Publication details

Associated with:

Advertising information

Would you like to advertise in Expert Review of Anticancer Therapy?

Ready to submit?

Information for

Open access

Opportunities

Help and information

Keep up to date